FMP
TCR2 Therapeutics Inc.
TCRR
NASDAQ
Inactive Equity
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
1.48 USD
0 (0%)
TCRR Financial Statements
Quarter
2023 Q1
2022 Q4
2022 Q3
2022 Q2
Total Revenue
0
0
0
0
Cost of Revenue
0
0
0
0
Gross Profit
0
0
0
0
Operating Expenses
37.47M
31.54M
31.1M
31.77M
Research and Development
29.27M
25.74M
24.79M
25.77M
Selling, General & Administrative Expenses
8.2M
5.8M
6.31M
6M
Selling & Marketing Expenses
0
0
0
0
General & Administrative Expenses
8.2M
5.8M
6.31M
6M
Other Expenses
4.04M
30.42M
0
0
Operating Income
-41.51M
-61.42M
-31.1M
-31.77M
Total Other Income/Expenses Net
1.11M
1.01M
510k
298k
Income Before Tax
-40.4M
-60.41M
-30.59M
-31.47M
Income Tax
3k
96k
1k
128k
Net Income
-40.4M
-60.51M
-30.59M
-31.6M
Basic EPS
-1.03
-1.56
-0.79
-0.82
EPS Diluted
-1.03
-1.56
-0.79
-0.82
Basic Average Shares
39.22M
38.81M
38.62M
38.57M
Diluted Average Shares
39.22M
38.81M
38.62M
38.57M
EBITDA
-32.81M
-1.66M
-30.21M
-31.07M
Retained Earning Schedule
Quarter
2023 Q1
2022 Q4
2022 Q3
2022 Q2
Retained Earnings (Previous Year)
-501.34M
-440.84M
-410.25M
-378.64M
Net Income
-40.4M
-60.51M
-30.59M
-31.6M
Stock Repurchases
0
0
0
0
Dividend Paid
0
0
0
0
Retained Earnings
-541.74M
-501.34M
-440.84M
-410.25M
Other Distributions
-40.4M
-60.51M
-30.59M
-31.6M
PPE Schedule
Quarter
2023 Q1
2022 Q4
2022 Q3
2022 Q2
Gross PPE
9.15M
28.68M
86.79M
90M
Annual Depreciation
8.7M
59.77M
890k
704k
Capital Expenditure
-158k
-2.44M
-4.82M
-6.21M
Net PPE
614k
-28.65M
90.72M
95.51M
Intangible and Goodwill Schedule
Quarter
2023 Q1
2022 Q4
2022 Q3
2022 Q2
Acquisitions and Adjustments
0
0
0
0
Goodwill (Previous Year)
0
0
0
0
Goodwill
0
0
0
0
All figures are in USD.
